HANSEN-TECHNOLOGIES
20.12.2021 12:02:04 CET | Business Wire | Press release
Hansen Technologies (ASX:HSN) is pleased to announce a new agreement with Jämtkraft, a leading Swedish utility. As part of the agreement, Jämtkraft has selected Hansen Trade to cover day-ahead trading operations, and for monitoring short-term positions. Jämtkraft now joins Hansen’s family of over 600 global customers.
Hansen Trade Day-Ahead Trading streamlines Jämtkraft’s daily bidding process, maintains order structures and handles day-ahead trade results automatically. The Day-Ahead Trading solution enables order configurations to be tagged to specific assets; this means that it can disaggregate trade results from the portfolio level, right down to the individual asset, if needed. As a SaaS service, Hansen Trade Day-Ahead Trading is compliant with market changes and is connected to Nord Pool’s new auction platform, which goes live in the Nordics in early 2022.
Hansen Trade Position Visualisation enables Jämtkraft to monitor and analyse short-term positions in real-time. An example would be the root cause of imbalance volumes. The operator can view the total imbalance position on a price-area level, including colour-masking for exceptionally high or low values. The Position Visualisation solution then enables the operator to drill deeper to portfolio (such as production type), sub-portfolio (hydropower assets in the same river) and finally to the asset level, to examine the cause for exceptional values on the top level.
Andreas Wiklander, Head of Operations, Jämtkraft, commented: “With Hansen Trade, we can modernise our daily trading operations, and get better and easier visibility into our trading positions. At Jämtkraft, we were impressed with the demonstration of Hansen Trade’s features and coupled with the positive reception that the solution has received from several energy companies in the region – being a vital enabler of day-to-day trading operations – we are more than confident that Hansen Trade is the answer when it comes to addressing our challenge.”
Scott Weir, Regional President, EMEA, Hansen Technologies, commented: “We continue to see a major uptick in the deployment of Hansen Trade across the Nordic region. This new agreement with Jämtkraft, in addition to the strong endorsement from our other customers in the region, attests to the strength of Hansen and our solutions in addressing the complexities of the digital era.”
Jämtkraft’s selection of Hansen Trade follows other recent agreements with Fortum , Power-Deriva and Tampereen Sähkölaitos . Run as a modular, cloud-based SaaS solution, Hansen Trade fully meets the flexibility and scalability demands of the evolving energy trading market.
For further information about Hansen Technologies, please visit www.hansencx.com .
About Hansen Technologies
Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy, water and communications industries. With its award-winning software portfolio, Hansen serves 600+ customers in over 80 countries, helping them to create, sell and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com
About Jämtkraft
Jämtkraft AB is a utilities company based in Jämtland, Sweden. The company is owned by the municipalities of Åre, Krokom and Östersund. Jämtkraft AB engages in producing, distributing and selling electric power to residential and business customers throughout Sweden. Renewable district heating is also part of the business portfolio. Jämtkraft AB has a long tradition of focusing on sustainability and climate-smart living, as well as sustainable and long-term business.
For more information, visit https://www.jamtkraft.se/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom